PannTheraPi

Executive Summary

PannTheraPi is a clinical-stage biotech company headquartered in Paris, France, founded in 2019. The company is pioneering the development of first-in-class small molecule drugs that selectively target the activated pannexin 1 channel, a novel mechanism for treating neurological and psychiatric disorders. Its lead program addresses a pediatric orphan epileptic syndrome with high unmet need, leveraging a differentiated biology that could reduce side effects compared to broad-spectrum anticonvulsants. The company is currently in Phase 1 clinical development, focusing on safety and proof-of-mechanism. Backed by its innovative platform, PannTheraPi aims to expand into other neuroinflammatory and neurodegenerative conditions, positioning itself as a leader in pannexin-targeted therapies.

Upcoming Catalysts (preview)

• H2 2026Phase 1 Topline Data for Lead Epilepsy Candidate60% success
• H1 2027Announcement of Next Indication Pipeline Candidate40% success
• TBDPotential Strategic Partnership or Licensing Deal30% success